» Articles » PMID: 35179699

Identification of Promising Multi-targeting Inhibitors of Obesity from Vernonia Amygdalina Through Computational Analysis

Overview
Journal Mol Divers
Date 2022 Feb 18
PMID 35179699
Authors
Affiliations
Soon will be listed here.
Abstract

Vernonia amygdalina, a widely consumed West African food herb, can be a boon in the discovery of safe anti-obesity agents given the extensive reports on its anti-obesity and antidiabetic potentials. The main aim of this study was to screen 78 Vernonia-Derived Phytocompounds (VDPs) against the active site regions of Human Pancreatic Lipase (HPL), Human Pancreatic Amylase and Human Glucosidase (HG) as drug targets associated with obesity in silico. Structure-based virtual screening helped to identify Luteolin 7-O-glucuronoside and Andrographidoid D2 as hit compounds with dual targeting tendency towards the HPL and HG. Analysis of the molecular dynamic simulation trajectory files of the ligand-receptor complexes as computed from the thermodynamic parameters plots showed not only increased flexibility and greater interaction potential of the active site residues of the receptor towards the VDPs as indicated by the root mean square fluctuation but also higher stability as indicated by the root mean square deviation, radius of gyration and number of hydrogen bonds. The cluster analysis further showed that the interactions with important residues were preserved in the dynamic environment. These observations were further verified from Molecular Mechanics Generalized Born Surface Area Analysis, which also showed that residual contributions to the binding free energies were mainly from catalytic residues at the active sites of the enzymes. The hit compounds also feature desirable physicochemical properties and drug-likeness. This study provides in silico evidence for the inhibitory potential of phytochemicals from Vernonia amygdalina against two target enzymes in obesity.

Citing Articles

Pharmacological Significance, Medicinal Use, and Toxicity of Extracted and Isolated Compounds from Species Found in Southern Africa: A Review.

Kgosiemang I, Lefojane R, Adegoke A, Ogunyemi O, Mashele S, Sekhoacha M Plants (Basel). 2025; 14(3).

PMID: 39943031 PMC: 11821031. DOI: 10.3390/plants14030469.


Lucidin from Outperforms FDA-Approved Lapatinib as a Potential Multitargeted Candidate for Breast Cancer Signalling Proteins.

Aloqbi A, Alahdal H, Alqosaibi A, Alnamshan M, Al-Dhuayan I, Al-Eidan A Pharmaceuticals (Basel). 2025; 18(1).

PMID: 39861131 PMC: 11768784. DOI: 10.3390/ph18010068.


Identification of promising dipeptidyl peptidase-4 and protein tyrosine phosphatase 1B inhibitors from selected terpenoids through molecular modeling.

Ogunyemi O, Gyebi G, Olawale F, Ibrahim I, Iwaloye O, Fabusiwa M Bioinform Adv. 2025; 5(1):vbae205.

PMID: 39846080 PMC: 11751579. DOI: 10.1093/bioadv/vbae205.


Network Pharmacology, Molecular Dynamics and In Vitro Assessments of Indigenous Herbal Formulations for Alzheimer's Therapy.

Ojo O, Ajayi-Odoko O, Gyebi G, Ayokunle D, Ogunlakin A, Ezenabor E Life (Basel). 2024; 14(10).

PMID: 39459522 PMC: 11508826. DOI: 10.3390/life14101222.


Cholinergic Inhibition and Antioxidant Potential of Gongronema latifolium Benth Leaf in Neurodegeneration: Experimental and In Silico Study.

Gyebi G, Ejoh J, Ogunyemi O, Afolabi S, Ibrahim I, Anyanwu G Cell Biochem Biophys. 2024; 83(1):1-23.

PMID: 39120857 DOI: 10.1007/s12013-024-01467-7.